Short answer
STAAR SURGICAL CO (STAA) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Press release announces STAAR Surgical’s financial results for the quarter ended October 2, 2026.
STAAR SURGICAL CO 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces STAAR Surgical’s financial results for the quarter ended October 2, 2026
- Detailed revenue, earnings, guidance and operating metrics appear in Exhibit 99.1, the key investor reference
Item 7.01 · Regulation FD Disclosure
- Management conference call scheduled November 4, 2026 at 5:30 p.m. Eastern
- Discussion covers quarterly results for the period ended October 2, 2026
- CEO and CFO participation signals investor focus on operating performance and outlook
Item EX-99.1 · Exhibit EX-99.1
- Q3 sales $83.4M, down 12% reported but up 21% excluding $25.9M of prior-year deferred China revenue
- China sales $39.3M, down 30% reported but up 31% on comparable basis, signaling underlying market-share gains
- Gross margin 70.9% versus adjusted prior-year 75.5%, pressured by tariffs, freight, ERP disruption, and inventory provisions
- Cash and investments $206.4M with no debt, supporting product investment and the newly authorized $50M share repurchase
- Presbyopia pipeline advances, with first-in-human trials for two products expected to begin enrollment in coming months
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other STAAR SURGICAL CO 8-K filings
Get the next STAA 8-K as it lands
Follow STAA for push alerts, or ask the research agent what this filing means.